Literature DB >> 17692951

Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation.

Mehmet Ozaydin1, Ozkan Dede, Ercan Varol, Sahin Kapan, Yasin Turker, Oktay Peker, Harun Duver, Erdogan Ibrisim.   

Abstract

BACKGROUND: No randomized studies have been conducted to evaluate the effects of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation (AF). The aim of this study was to evaluate the effect of angiotensin converting-enzyme inhibitors (ACEIs) and ACEI plus candesartan, an angiotensin receptor blocker on postoperative AF.
METHODS: A group of consecutive patients undergoing coronary artery bypass and/or valve surgery was studied (n=128). The patients were randomized to ACEI group (n=49) and ACEI plus candesartan group (n=49). Thirty patients not on ACEI or angiotensin receptor blocker constituted the control group.
RESULTS: The rate of postoperative AF was higher in the control group (33.3%) compared to the ACEI group (12.2%, p=0.02) or ACEI plus candesartan group (10.2%, p=0.01). With the Cox proportional model, univariable negative predictors of postoperative AF, were the use of ACEI (RR 0.34, 95% CI 0.12 to 0.93, p=0.03) and the use of ACEI plus candesartan (RR 0.28, 95% CI 0.09 to 0.83, p=0.02); the positive predictor of postoperative AF was age>or=65 (RR 3.10, 95% CI 1.30 to 7.37, p=0.01). With the multivariable Cox proportional model, the only predictor of postoperative AF was age>or=65 (RR 9.70, 95% CI 2.04 to 46.1, p=0.004).
CONCLUSION: ACEI alone and ACEI plus candesartan decrease the incidence of postoperative AF compared to the control group. Candesartan has no additional effect on the rates of postoperative AF when added to ACEI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692951     DOI: 10.1016/j.ijcard.2007.05.012

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Post-operative Atrial Fibrillation - Pathophysiology, Treatment and Prevention.

Authors:  E Bidar; S Bramer; B Maesen; J G Maessen; U Schotten
Journal:  J Atr Fibrillation       Date:  2013-04-06

Review 2.  Primary Prevention of Atrial Fibrillation where are we in 2012?

Authors:  Massimo Imazio
Journal:  J Atr Fibrillation       Date:  2012-08-20

3.  Atrial fibrillation and inflammation.

Authors:  Mehmet Ozaydin
Journal:  World J Cardiol       Date:  2010-08-26

Review 4.  Pharmacological strategies for prevention of postoperative atrial fibrillation.

Authors:  Mohit K Turagam; Francis X Downey; David C Kress; Jasbir Sra; A Jamil Tajik; Arshad Jahangir
Journal:  Expert Rev Clin Pharmacol       Date:  2015-03       Impact factor: 5.045

5.  Preoperative angiotensin-blocking drug therapy is not associated with atrial fibrillation after cardiac surgery.

Authors:  Florian Rader; David R Van Wagoner; A Marc Gillinov; Eugene H Blackstone
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

Review 6.  Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial Fibrillation: An Update.

Authors:  Alejandra Gutierrez; David R Van Wagoner
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

Review 7.  The Role Of Renin Angiotensin System In Atrial Fibrillation.

Authors:  Girish M Nair; Pablo B Nery; Calum J Redpath; David H Birnie
Journal:  J Atr Fibrillation       Date:  2014-04-30

8.  Relationship between Angiotensin Converting Enzyme, Apelin, and New-Onset Atrial Fibrillation after Off-Pump Coronary Artery Bypass Grafting.

Authors:  Shu Xu; Jian Zhang; Yin-Li Xu; Hai-Bo Wu; Xiao-Dong Xue; Hui-Shan Wang
Journal:  Biomed Res Int       Date:  2017-02-12       Impact factor: 3.411

9.  Author`s Reply.

Authors:  Çetin Geçmen
Journal:  Anatol J Cardiol       Date:  2016-11       Impact factor: 1.596

10.  Fish oil and atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Wei Xin; Wei Wei; Zhiqin Lin; Xiaoxia Zhang; Hongxia Yang; Tao Zhang; Bin Li; Shuhua Mi
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.